ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print June 25, 2008, 10.1183/09031936.00012408
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mannino, D. M.
Right arrow Articles by Holguin, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mannino, D. M.
Right arrow Articles by Holguin, F.
Eur Respir J 2008; 32:962-969
Copyright ©ERS Journals Ltd 2008

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

D. M. Mannino1, D. Thorn2, A. Swensen2 and F. Holguin3

1 Dept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, and 3 Emory University College of Medicine, Atlanta, GA, USA.

CORRESPONDENCE: D. M. Mannino, Dept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, 121 Washington Avenue, Lexington, KY 40536, USA. Fax: 1 8592571044. E-mail: dmannino{at}uky.edu

Keywords: Cardiovascular, diabetes, hypertension, lung function, mortality

Received: January 25, 2008
Accepted June 5, 2008

Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including cardiovascular disease, diabetes and hypertension.

The present study analysed data from 20,296 subjects aged ≥45 yrs at baseline in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS). The sample was stratified based on baseline lung function data, according to modified Global Initiative for Obstructive Lung Disease (GOLD) criteria. Comorbid disease at baseline and death and hospitalisations over a 5-yr follow-up were then searched for.

Lung function impairment was found to be associated with more comorbid disease. In logistic regression models adjusting for age, sex, race, smoking, body mass index and education, subjects with GOLD stage 3 or 4 COPD had a higher prevalence of diabetes (odds ratio (OR) 1.5, 95% confidence interval (CI) 1.1–1.9), hypertension (OR 1.6, 95% CI 1.3–1.9) and cardiovascular disease (OR 2.4, 95% CI 1.9–3.0). Comorbid disease was associated with a higher risk of hospitalisation and mortality that was worse in people with impaired lung function.

Lung function impairment is associated with a higher risk of comorbid disease, which contributes to a higher risk of adverse outcomes of mortality and hospitalisations.




This article has been cited by other articles:


Home page
Eur Respir JHome page
P. J. Barnes and B. R. Celli
Systemic manifestations and comorbidities of COPD
Eur. Respir. J., May 1, 2009; 33(5): 1165 - 1185.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. D Maclay, R. A Rabinovich, and W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2008
Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 533 - 541.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. Leone, D. Courbon, F. Thomas, K. Bean, B. Jego, B. Leynaert, L. Guize, and M. Zureik
Lung Function Impairment and Metabolic Syndrome: The Critical Role of Abdominal Obesity
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 509 - 516.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the European Respiratory Society.